Since 13 May 2022, rising cases of monkeypox have been reported to the World Health Organization (WHO) across the United Kingdom and Europe, and even some cases in the US and Canada. Based on currently available information, cases have mainly but not exclusively been identified amongst men who have sex with men seeking care in primary care and sexual health clinics.1
touchINFECTIOUS DISEASES spoke with Dr Christoph Boesecke (University of Bonn, Bonn, Germany) to discuss the rising cases of monkeypox in the UK and Europe, the populations at highest risk and the clinical presentation of the disease such as patients presenting with an atypical rash that progresses in sequential stages – macules, papules, vesicles, pustules, scabs, at the same stage of development over all affected areas of the body.1 Dr Boesecke also discusses the current UK and EU guidelines and regulations around monkeypox.
- How many cases of monkeypox have been identified and what do you consider the current risk to public health? (0:24)
- Which populations are at highest risk of contracting the disease? (1:19)
- What is the usual clinical presentation of monkeypox and are current cases presenting with the typical symptoms? (1:45)
- What do you consider the reasons for the rapid pace of this epidemic? (2:44)
- What are the current UK and EU regulations around monkeypox? (3:34)
Disclosures: Dr Christoph Boesecke has nothing to disclose in relation to this video interview
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
- World Health Organization. Multi-country monkeypox outbreak in non-endemic countries. 2022. Available at: www.who.int/emergencies/disease-outbreak-news/item/2022-DON385 (accessed 17 June 2022).
Share this Video
Related Videos In Viral Infections
DANFLU-1: post-hoc analysis of high-dose quadrivalent influenza vaccines: Niklas Dyrby Johansen, ECCMID 2023
DANFLU-1 was an open-label, active-controlled, individually randomized trial conducted in Denmark during the 2021/2022 northern hemisphere influenza season. Dr Niklas Dyrby Johansen (University of Copenhagen Copenhagen, Denmark) discusses the post-hoc analysis from DANFLU-1 which investigated the effects of high-dose quadrivalent influenza vaccine (QIV-HD) vs standard-dose quadrivalent influenza vaccine (QIV-SD). The abstract ‘Relative effectiveness of high-dose […]
Michael Ison, IDWeek 2022: Respiratory syncytial virus (RSV) – Health burden and current vaccine candidates
Respiratory syncytial virus (RSV) present a significant disease burden in children and older adults. Currently, there are no approved vaccines against RSV. In this touchINFECTIOUS DISEASES interview, we met with Prof. Michael Ison (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss the health burden of RSV infection in older adults, and current […]
Michael Ison, IDWeek 2022: Respiratory syncytial virus (RSV) prefusion F protein candidate vaccine RSVPreF3 OA – Ongoing phase 3 study results
Respiratory syncytial virus (RSV) presents a significant disease burden in older adults, with no approved vaccines to protect against RSV. In this touchINFECTIOUS DISEASES interview, we met with Prof. Michael Ison (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss the findings from an ongoing phase 3 study investigating vaccine efficacy of the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!